Schizophrenia Trial, Recruiting NCT07428460 Sponsor: Douglas Mental Health University Institute Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT07428460
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder
  • People whose illness has lasted for 6 months or longer
  • People who have significant "negative symptoms" (such as reduced motivation, emotion, or speech — confirm with trial site for specifics)
  • People who have been on a stable medication plan for at least 4 weeks before the study begins
  • People whose symptoms (both positive and negative) have been considered stable by their treating clinician for at least 3 months
  • People who are able to give informed consent to participate
  • People who are able to have an MRI scan

Who may not be able to join:

  • People who are pregnant, breastfeeding, or using an intrauterine device (IUD)
  • People who have had electroconvulsive therapy (ECT) within the past 6 months
  • People who have used alcohol or other substances (apart from cannabis) during the week of treatment or within 24 hours before a brain scan
  • People who have medical reasons that make a type of brain stimulation called TMS unsafe for them (confirm with trial site for specifics)
  • People who have previously received a treatment called rTMS (repetitive transcranial magnetic stimulation)
  • People who have a documented history of significant intellectual disability
  • People whose primary diagnosis is a psychotic disorder caused by a medical condition or by substance use

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Douglas Mental Health University Institute
Registry
ClinicalTrials.gov
Start date
1 February 2026
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Change in Avolition/Apathy Subscale Score; Change in Scale for the Assessment of Negative Symptoms Total Score; Change in Brief Negative Symptom Scale Total Score; Effect of Targeting Method on Negative Symptoms

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov